QPathology (QPath)

A Next Generation in Medical Services Company

Research-focused TMA Biobank

Develop and maintain a biobank of formalin-fixed Tissue Microarrays (TMAs)

  • unique position, long expertise in TMA development (QPath Founder O. Bucur)
  • for research purpose only, for us and our partners
Other ideas we are exploring: Pathology Services and Collaborative Platform

Consultancy

Members of our team are also founders and collaborators of Global Academic Consulting, providing a range of consultancy services in the search and selection of Senior Administrators for Academic Institutions, the establishment of Research Centers and Academic Institutions, launching of Biotech Companies.

Team

Octavian Bucur, MD, PhD

Co-founder and CEO

Former Instructor in Pathology, BIDMC, Harvard Medical School, Boston, MA, USA; expert in biomedical technology development, molecular and computational pathology; co-Editor in Chief of Discoveries journal

Bhanu P. Jena, PhD

Co-founder and President

Director of the NanoBioScience Institute, Founder of Several Research Institutes throughout the world; George E. Palade University Professor & Distinguished Professor, Wayne State University, Detroit, MI, USA

Advisors

John D. Halamka, MD, MS

Healthcare Technology Expert

CIO of BIDMC, Dean of Technology at Harvard Medical School, Chairman of the Healthcare IT Standards Panel, Editor-in-Chief of Blockchain in Healthcare Today

Victor E. Velculescu MD, PhD

Cancer Genetics Expert

Founder of the Personal Genome Diagnostics (PGDx) and Co-Director of Cancer Biology at the Johns Hopkins University, Baltimore, MD, USA

George M. Church, PhD

Genetics & Molecular Engineering

"Father of synthetic biology". Professor of Genetics at Harvard Medical School; Professor at MIT, Director of the NIH Center of Excellence in Genomic Science (Harvard), Founder of >8 and Advisor for >10 companies.

Alex Almasan, PhD

Molecular Oncology Expert

Professor of Molecular Medicine, Co-Leader of Molecular Oncology program, Department of Cancer Biology, Cleveland Clinic & CWRU, Cleveland, OH, USA

Lars Larsson, MD PhD

Clinical Expert

Professor, Department of Physiology and Pharmacology, Senior Consultant, Clinical Neuroscience, Karolinska Institutet and Karolinska Hospital, Stockholm, Sweden

Product Pipeline

Prof. Bhanu P. Jena has developed a formulation (“Patent Pending”) to mitigate infection by enveloped viruses, such as HIV and Covid-19. The active constituent used in this water-based formulation is a U.S. Food and Drug Administration (FDA) approved product, which is currently in use in over 40 pharmaceutical drugs, administered either via oral, nasal, pulmonary, ocular, anal or dermal routes. The proposed effective dose of the active constituent in the formulation to be administered falls within the FDA-specified guidelines. The proposed route of administration of the formulation is dermal, nasal and pulmonary, using a soft mist inhaler to deliver a precise dose. The formulation is engineered to remain sterile in absence of toxic preservatives, such as benzalkonium chloride, commonly used in nasal, inhalable, ophthalmic and topical preparations in current use. The formulation has the additional potential of mitigating bacterial and fungal infections. A randomized double- blind placebo-controlled clinical study will soon be conducted. In addition to having a potential in mitigating the actual Covid-19 crisis, the formulation holds great promise for its use by health care providers. The challenge of overcoming infection by a mutated enveloped virus, such as Covid-19 and HIV, could potentially be addressed, at least in part, using this formulation. Hence, in addition to its potential benefit for society by mitigating the current Covid-19 crisis, the formulation has a huge global market potential. The current global market for the anti-infective agents is valued at $120B.

QPathology has developed a precise, rapid and inexpensive nanothermometry approach (“Patent Pending”) for detection of cancer cells. The current global market for cancer detection is valued at $150B, which is expected to reach $250B in 2026.

Rapid urbanization resulting in increased population density combined with socioeconomic disparities is threatening global health. According to the World Health Organization, the major health challenges facing cities today are from infectious diseases, such as hepatitis, tuberculosis, pneumonia, and antibiotic resistance. QPathology has developed an inexpensive nanoscale thermometry approach, for precise bacterial strain- detection. Development of an automated Tool-kit is aimed for the use in clinics, even in the most remote corners of the world. The current diagnostic market for microbial detection is valued at $5B.

Expensive and time-consuming approaches of immunoelectron microscopy-based investigation of tissue biopsies continues to play an important diagnostic and confirmatory role in diagnostic pathology. The recent development by QPathology of the new approach of Differential Expansion Microscopy (DiExM) combined with machine learning-based image analysis, will change (rapid, precise and automated) how disease is detected in pathological human specimens. The current global market for disease detection using histopathology is valued at $33B.

QPathology has identified and is optimizing a repurposed drug to overcome depleted oxygen transport in red blood cells during hypercholesterolemia.

QPathology is developing a Tissue MicroArray (TMA) Biobank. The current global market for TMA is valued at $225B.

Roadmap

2017
T4

First discussions and brainstorming sessions between founders

2018
T1

Design and strategy

T2

Core Team and Advisory Board established, website launched

T2

QPathology registered in MA

2019
T1

Cancer Detection Tool Kit using Nano-thermometry initiated

T4

Tissue microarray biobank is initiated

T4

Provisional Patent on Nano-thermometry for Cancer Detection filed & NIH collaboration initiated

2020
T2

Development of a lotion for preventing viral entry

T4

Provisional Patent on a topological lotion preventing viral entry

T4

1st Retreat of QPath to evaluate its progress and strategy